Allogeneic blood transfusion and prognosis following total hip replacement: a population-based follow up study

Alma B Pedersen, Frank Mehnert, Soren Overgaard, Soren P Johnsen, Alma B Pedersen, Frank Mehnert, Soren Overgaard, Soren P Johnsen

Abstract

Background: Allogeneic red blood cell transfusion is frequently used in total hip replacement surgery (THR). However, data on the prognosis of transfused patients are sparse. In this study we compared the risk of complications following THR in transfused and non-transfused patients.

Methods: A population-based follow-up study was performed using data from medical databases in Denmark. We identified 28,087 primary THR procedures performed from 1999 to 2007, from which we computed a propensity score for red blood cell transfusion based on detailed data on patient-, procedure-, and hospital-related characteristics. We were able to match 2,254 transfused with 2,254 non-transfused THR patients using the propensity score.

Results: Of the 28,087 THR patients, 9,063 (32.3%) received at least one red blood cell transfusion within 8 days of surgery. Transfused patients had higher 90-day mortality compared with matched non-transfused patients: the adjusted OR was 2.2 (95% confidence interval (CI): 1.2-3.8). Blood transfusion was also associated with increased odds of pneumonia (OR 2.1; CI: 1.2-3.8), whereas the associations with cardiovascular or cerebrovascular events (OR 1.4; CI: 0.9-2.2) and venous thromboembolism (OR 1.2; CI: 0.7-2.1) did not reach statistical significance. The adjusted OR of reoperation due to infection was 0.6 (CI: 0.1-2.9).

Conclusions: Red blood cell transfusion was associated with an adverse prognosis following primary THR, in particular with increased odds of death and pneumonia. Although the odds estimates may partly reflect unmeasured bias due to blood loss, they indicate the need for careful assessment of the risk versus benefit of transfusion even in relation to routine THR procedures.

Figures

Figure 1
Figure 1
Crude and adjusted odds ratios of adverse outcomes within 90 days of primary total hip replacement (THR) associated with red blood cell transfusion among propensity score matched patients. Submitted and labelled separately. Legend: * odds ratio with 95% confidence interval. ** odds ratio adjusted for haemoglobin concentration 1-7 days postoperative. Reference group is non-transfused patients.

References

    1. Lohmander LS, Engesaeter LB, Herberts P, Ingvarsson T, Lucht U, Puolakka TJ. Standardized incidence rates of total hip replacement for primary hip osteoarthritis in the 5 Nordic countries: similarities and differences. Acta Orthop. 2006;77:733–740. doi: 10.1080/17453670610012917.
    1. Mahomed NN, Barrett JA, Katz JN, Phillips CB, Losina E, Lew RA, Guadagnoli E, Harris WH, Poss R, Baron JA. Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Joint Surg Am. 2003;85-A:27–32.
    1. Pedersen AB, Johnsen SP, Overgaard S, Soballe K, Sorensen HT, Lucht U. Total hip arthroplasty in Denmark. Incidence of primary operations and revisions 1996-2002 and estimated future demands. Acta Orthopaedica. 2005;76:182–189. doi: 10.1080/00016470510030553.
    1. Hasley PB, Lave JR, Hanusa BH, Arena VC, Ramsey G, Kapoor WN, Fine MJ. Variation in the use of red blood cell transfusions. A study of four common medical and surgical conditions. Med Care. 1995;33:1145–1160. doi: 10.1097/00005650-199511000-00007.
    1. The Sanguis Study Group. Use of blood products for elective surgery in 43 European hospitals. Transfusion Medicine. 1994;4:251–268. doi: 10.1111/j.1365-3148.1994.tb00262.x.
    1. Koch CG, Li L, Duncan AI, Mihaljevic T, Cosgrove DM, Loop FD, Starr NJ, Blackstone EH. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med. 2006;34:1608–1616. doi: 10.1097/01.CCM.0000217920.48559.D8.
    1. Kuduvalli M, Oo AY, Newall N, Grayson AD, Jackson M, Desmond MJ, Fabri BM, Rashid A. Effect of peri-operative red blood cell transfusion on 30-day and 1-year mortality following coronary artery bypass surgery. Eur J Cardiothorac Surg. 2005;27:592–598. doi: 10.1016/j.ejcts.2005.01.030.
    1. Malone DL, Dunne J, Tracy JK, Putnam AT, Scalea TM, Napolitano LM. Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J Trauma. 2003;54:898–905. doi: 10.1097/01.TA.0000060261.10597.5C.
    1. Robinson WP III, Ahn J, Stiffler A, Rutherford EJ, Hurd H, Zarzaur BL, Baker CC, Meyer AA, Rich PB. Blood transfusion is an independent predictor of increased mortality in nonoperatively managed blunt hepatic and splenic injuries. J Trauma. 2005;58:437–444. doi: 10.1097/01.TA.0000153935.18997.14.
    1. Audet AM, Andrzejewski C, Popovsky MA. Red blood cell transfusion practices in patients undergoing orthopedic surgery: a multi-institutional analysis. Orthopedics. 1998;21:851–858.
    1. Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am. 1999;81:2–10.
    1. Carson JL, Altman DG, Duff A, Noveck H, Weinstein MP, Sonnenberg FA, Hudson JI, Provenzano G. Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion. 1999;39:694–700. doi: 10.1046/j.1537-2995.1999.39070694.x.
    1. Dunne JR, Malone DL, Tracy JK, Napolitano LM. Allogenic blood transfusion in the first 24 hours after trauma is associated with increased systemic inflammatory response syndrome (SIRS) and death. Surg Infect (Larchmt) 2004;5:395–404. doi: 10.1089/sur.2004.5.395.
    1. Innerhofer P, Klingler A, Klimmer C, Fries D, Nussbaumer W. Risk for postoperative infection after transfusion of white blood cell-filtered allogeneic or autologous blood components in orthopedic patients undergoing primary arthroplasty. Transfusion. 2005;45:103–110. doi: 10.1111/j.1537-2995.2005.04149.x.
    1. Johnston P, Wynn-Jones H, Chakravarty D, Boyle A, Parker MJ. Is perioperative blood transfusion a risk factor for mortality or infection after hip fracture? J Orthop Trauma. 2006;20:675–679. doi: 10.1097/01.bot.0000249435.25751.e8.
    1. Pedersen A, Johnsen S, Overgaard S, Soballe K, Sorensen H, Lucht U. Registration in the Danish Hip Arthroplasty Registry: Completeness of total hip arthroplasties and positive predictive value of registered diagnosis and postoperative complications. Acta Orthop Scand. 2004;75:434–441.
    1. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. 2006;53:441–449.
    1. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163:1149–1156. doi: 10.1093/aje/kwj149.
    1. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–2281. doi: 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>;2-B.
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383. doi: 10.1016/0021-9681(87)90171-8.
    1. Joensen AM, Jensen MK, Overvad K, Dethlefsen C, Schmidt E, Rasmussen L, Tjonneland A, Johnsen S. Predictive values of acute coronary syndrome discharge diagnoses differed in the Danish National Patient Registry. J Clin Epidemiol. 2009;62:188–194. doi: 10.1016/j.jclinepi.2008.03.005.
    1. Thomsen RW, Hundborg HH, Lervang HH, Johnsen SP, Sorensen HT, Schonheyder HC. Diabetes and outcome of community-acquired pneumococcal bacteremia: a 10-year population-based cohort study. Diabetes Care. 2004;27:70–76. doi: 10.2337/diacare.27.1.70.
    1. Thomsen RW, Riis A, Norgaard M, Jacobsen J, Christensen S, McDonald CJ, Sorensen HT. Rising incidence and persistently high mortality of hospitalized pneumonia: a 10-year population-based study in Denmark. J Intern Med. 2006;259:410–417. doi: 10.1111/j.1365-2796.2006.01629.x.
    1. Thygesen SK, Christiansen CF, Lash TL, Christensen S, Sorensen HT. The predictive value of ICD-10 diagnoses in population-based hospital registries used to assess Charlson Comorbidity Index. Pharmacoepidemiology and drug safety. 2009;18(Suppl 1):189.
    1. Danish Medicines Agency. Redegørelse for blodproduktområdet 2007. Copenhagen. 2008.
    1. Pedersen AB, Mehnert F, Overgaard S, Moller B, Johnsen SP. [Transfusion practice in total hip arthroplasty in Danish departments of orthopaedic surgery] Ugeskr Laeger. 2009;171:973–977.
    1. Rana R, Fernandez-Perez ER, Khan SA, Rana S, Winters JL, Lesnick TG, Moore SB, Gajic O. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion. 2006;46:1478–1483. doi: 10.1111/j.1537-2995.2006.00930.x.
    1. Barrett J, Losina E, Baron JA, Mahomed NN, Wright J, Katz JN. Survival following total hip replacement. J Bone Joint Surg Am. 2005;87:1965–1971. doi: 10.2106/JBJS.D.02440.
    1. Koch CG, Li L, Duncan AI, Mihaljevic T, Loop FD, Starr NJ, Blackstone EH. Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg. 2006;81:1650–1657. doi: 10.1016/j.athoracsur.2005.12.037.
    1. Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, Blackstone EH. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008;358:1229–1239. doi: 10.1056/NEJMoa070403.
    1. Vamvakas EC, Moore SB, Cabanela M. Blood transfusion and septic complications after hip replacement surgery. Transfusion. 1995;35:150–156. doi: 10.1046/j.1537-2995.1995.35295125738.x.
    1. Vamvakas EC. Pneumonia as a complication of blood product transfusion in the critically ill: transfusion-related immunomodulation (TRIM) Crit Care Med. 2006;34:S151–S159. doi: 10.1097/01.CCM.0000214310.70642.8C.
    1. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med. 2008;36:2667–2674. doi: 10.1097/CCM.0b013e3181844677.
    1. Aderinto J, Brenkel IJ. Pre-operative predictors of the requirement for blood transfusion following total hip replacement. J Bone Joint Surg Br. 2004;86:970–973. doi: 10.1302/0301-620X.86B7.14682.
    1. Pola E, Papaleo P, Santoliquido A, Gasparini G, Aulisa L, De SE. Clinical factors associated with an increased risk of perioperative blood transfusion in nonanemic patients undergoing total hip arthroplasty. J Bone Joint Surg Am. 2004;86-A:57–61.
    1. Singla I, Zahid M, Good CB, Macioce A, Sonel AF. Impact of blood transfusions in patients presenting with anemia and suspected acute coronary syndrome. Am J Cardiol. 2007;99:1119–1121. doi: 10.1016/j.amjcard.2006.11.056.
    1. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340:409–417. doi: 10.1056/NEJM199902113400601.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir